Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma

Giancarlo Bisagni, Giulio Rossi, Alberto Cavazza, Giuliana Sartori, Giorgio Gardini, Corrado Boni

Research output: Contribution to journalArticle

Abstract

Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-kit missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.

Original languageEnglish
Pages (from-to)773-775
Number of pages3
JournalJournal of Thoracic Oncology
Volume4
Issue number6
DOIs
Publication statusPublished - Jun 2009

Keywords

  • C-Kit
  • CD117
  • Thymic carcinoma
  • Thymoma
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma'. Together they form a unique fingerprint.

  • Cite this